Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma ...

MMRF continues to drive the critical global research collaborations that lead to scientific breakthroughs and improved patient outcomesNORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the ...

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy.

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies ...

Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that can improve the efficacy ...

Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate ...

Among 78 patients with relapsed or refractory disease, the 24-month relapse-free rate after treatment discontinuation was 68% ...